Liquidia Technologies Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT technology,  has entered into a common stock purchase agreement for $22.4 million.